1
|
Nandy S, Dey A. Bibenzyls and bisbybenzyls of bryophytic origin as promising source of novel therapeutics: pharmacology, synthesis and structure-activity. Daru 2020; 28:701-734. [PMID: 32803687 PMCID: PMC7429097 DOI: 10.1007/s40199-020-00341-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Accepted: 03/30/2020] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The amphibian, non-vascular, gametophyte-dominant, bio-indicator class, bryophytes; with their wide ranges of habitat have attained importance due to their promising medicinal attributions and therapeutic role; mostly aided by presence of aromatic bibenzyl and bisbybenzyl class of compounds. Bibenzyls are steroidal ethane derivatives, resembling the structural moiety of bioactive dihydro-stilbenoids or iso-quinoline alkaloids. These stress triggered secondary metabolites are the by-products of the flavonoid biosynthetic pathway. Different classes of bryophytes (Bryophyta, Marchantiophyta and Anthocerotophyta) possess different subtypes of bibenzyls and dimeric bisbibenzyls. Among the liverwort, hornwort and mosses, former one is mostly enriched with bibenzyl type constituents as per the extensive study conducted for phytochemical deposit. Considering macrocyclic and acyclic group of bibenzyls and bisbybenzyls, generally marchantin type compounds are reported vividly for significant biological activity that includes neuro-nephro-cardio-protection besides anti-allergic, anti-microbial, anti-apoptotic and cytotoxic activities studied on in-vitro and in-vivo models or on cell lines. RESULT The critical analysis of reported chemical and pharmaceutical attributions of bibenzyls and bis-bibenzyls yielded detailed report on this compound class along with their application, mode of action, natural source, techniques of synthesis, extraction procedure, isolation and characterization. Further, the structure activity relationship studies and bioactivity of bibenzyls derived from non-bryophytic origin were also summarized. CONCLUSION This review encompasses prospective biological application of botanical reservoir of this primarily ignored, primeval land plant group where recent technical advances has paved the way for qualitative and quantitative isolation and estimation of novel compounds as well as marker components to study their impact on environment, as bio-control agents and as key leads in future drug designing. Graphical abstract.
Collapse
Affiliation(s)
- Samapika Nandy
- Research Scholar, Department of Life Sciences, Presidency University, Kolkata, 700073 India
| | - Abhijit Dey
- Department of Life Sciences, Presidency University, Kolkata, 700073 India
| |
Collapse
|
2
|
Abstract
Multidrug resistance (MDR) has emerged as the main problem in anti-cancer therapy. Although MDR involves complex factors and processes, the main pivot is the expression of multidrug efflux pumps. P-glycoprotein (P-gp) belongs to the family of adenosine triphosphate (ATP)-binding cassette (ABC) transporters. It functions in cellular detoxification, pumping a wide range of xenobiotic compounds out of the cell. An attractive therapeutic strategy for overcoming MDR is to inhibit the transport function of P-gp and thus, increase intracellular concentration of drugs. Recently, various types of P-gp inhibitors have been found and used in experiments. However, none of them has passed clinical trials due to their high side-effects. Hence, the search for alternatives, such as plant-based P-gp inhibitors have gained attention recently. Therefore, we give an overview of the source, function, structure and mechanism of plant-based P-gp inhibitors and give more attention to cancer-related studies. These products could be the future potential drug candidates for further research as P-gp inhibitors.
Collapse
Affiliation(s)
- Jun Yu
- a Institute of Clinical Pharmacology, Anhui Medical University , Hefei , China .,b Key Laboratory of Antiinflammatory and Immune Medicine, Ministry of Education , Hefei , China , and.,c Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine , Hefei , China
| | - Peng Zhou
- a Institute of Clinical Pharmacology, Anhui Medical University , Hefei , China .,b Key Laboratory of Antiinflammatory and Immune Medicine, Ministry of Education , Hefei , China , and.,c Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine , Hefei , China
| | - James Asenso
- a Institute of Clinical Pharmacology, Anhui Medical University , Hefei , China .,b Key Laboratory of Antiinflammatory and Immune Medicine, Ministry of Education , Hefei , China , and.,c Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine , Hefei , China
| | - Xiao-Dan Yang
- a Institute of Clinical Pharmacology, Anhui Medical University , Hefei , China .,b Key Laboratory of Antiinflammatory and Immune Medicine, Ministry of Education , Hefei , China , and.,c Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine , Hefei , China
| | - Chun Wang
- a Institute of Clinical Pharmacology, Anhui Medical University , Hefei , China .,b Key Laboratory of Antiinflammatory and Immune Medicine, Ministry of Education , Hefei , China , and.,c Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine , Hefei , China
| | - Wei Wei
- a Institute of Clinical Pharmacology, Anhui Medical University , Hefei , China .,b Key Laboratory of Antiinflammatory and Immune Medicine, Ministry of Education , Hefei , China , and.,c Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine , Hefei , China
| |
Collapse
|
3
|
Cui SX, Zhang HL, Xu WF, Qu XJ. 13F-1, a novel 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO2) COOCH3 tripeptide, inhibits human colonic carcinoma growth by targeting Aminopeptidase N (APN/CD13). Eur J Pharmacol 2014; 734:50-9. [PMID: 24726845 DOI: 10.1016/j.ejphar.2014.04.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2013] [Revised: 04/02/2014] [Accepted: 04/03/2014] [Indexed: 12/27/2022]
Abstract
13F-1 is a 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO2) COOCH3 tripeptide. 13F-1 might possess the activity against cancer growth by targeting Aminopeptidase N (APN/CD13). Our goal in this study was to evaluate the inhibitory effect of 13F-1 on the growth of human colonic carcinoma by both in vitro and in vivo studies. Experiments were performed in colonic carcinoma Colo205 cells, which highly express APN/CD13 on cell surface. The inhibition of 13F-1 on cancer cell growth was estimated by the colorimetric and clonogenic assays. The assays of Annexin V-FITC/PI and JC-1 fluorescence probe were employed to determine the apoptotic cells. Further experiment was performed in mice bearing Colo205 xenografts. 13F-1 was injected for three consecutive weeks. The specimens of Colo205 xenografts were removed for TUNEL staining and western blotting analysis. The expressions of APN/CD13 were analyzed by immunofluorescent flow cytometry and western blotting assays. 13F-1 significantly inhibited Colo205 cell proliferation. 13F-1 by injection delayed the expansion of Colo205 xenografts without significant toxicity to mice. The inhibitory effect of 13F-1 might arise from its role in apoptotic induction. Further analysis indicated that 13F-1 strongly inhibited APN/CD13 expression on cancer cell surface. In contrast, 5-FU did not affect APN/CD13 expression. These results indicated the mechanism of 13F-1 action that 13F-1׳s effect was associated with its role in suppression of APN/CD13 expression. Conclusion, 13F-1 could be developed as a promising agent for treatment of cancers with high expression of APN/CD13.
Collapse
|
4
|
Yue B, Zhao CR, Xu HM, Li YY, Cheng YN, Ke HN, Yuan Y, Wang RQ, Shi YQ, Lou HX, Qu XJ. Riccardin D-26, a synthesized macrocyclic bisbibenzyl compound, inhibits human oral squamous carcinoma cells KB and KB/VCR: In vitro and in vivo studies. Biochim Biophys Acta Gen Subj 2013; 1830:2194-203. [DOI: 10.1016/j.bbagen.2012.10.011] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2012] [Revised: 10/04/2012] [Accepted: 10/11/2012] [Indexed: 01/08/2023]
|